PD-L1 anticorps

N° du produit ABIN1106177

L’anticorps Souris Monoclonal anti-PD-L1 a été validé pour FACS. Il convient pour détecter PD-L1 dans des échantillons de Humain.

Aperçu rapide pour PD-L1 anticorps (ABIN1106177)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est non-conjugé

Application: Flow Cytometry (FACS)

Clone: MIH3

Détail du produit anti-PD-L1 anticorps

Specificité: This antibody reacts with human CD274 antigen.

Purification: Protein A agarose

Immunogène: Full-length human PD-L1 transfected L cells

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: PBS containing 50 % glycerol, pH 7.2. Contains no preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: Store (in aliquots) at -20 °C.

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: CD274 / PDL1

Sujet: Programmed death ligand 1 (PD-L1, also known as CD274/B7-H1), a member of B7 family was identified by searching for molecules that share homology with the immunoglobulin V and C domains of B7-1 and B7-2 among the human cDNA expressed sequence tags in the National Center for Biotechnology Information database. PD-L1 is a ligand for programmed death 1 (PD-1) which belongs to the CD28/CTLA4 subfamily. Although in vitro study indicated that the cross-linking of PD-1 by PD-L1 leads to down-regulation of T-cell responses, some studies have shown that T cells stimulated with low levels of anti-CD3 and immobilized PD-L1-Ig were activated, proliferation and production of IFN-γ, GM-CSF and IL-10 from the T cells were enhanced.Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1

ID gène: 29126

NCBI Accession: NP_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints